BCAL Diagnostics (ASX:BDX) EBIT: A$-7.03 Mil (TTM As of Dec. 2025)


What is BCAL Diagnostics EBIT?

BCAL Diagnostics ASX:BDX +10.96% EBIT is A$-7.03 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

BCAL Diagnostics's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$-3.79 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-7.03 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BCAL Diagnostics's annualized ROC % for the quarter that ended in Dec. 2025 was -259.75%. BCAL Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -214.25%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BCAL Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -23.47%.

BCAL Diagnostics  (ASX:BDX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BCAL Diagnostics's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-10.038 * ( 1 - 0% )/( (4.625 + 3.104)/ 2 )
=-10.038/3.8645
=-259.75 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9.909 - 1.197 - ( 4.523 - max(0, 3.108 - 7.195+4.523))
=4.625

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7.173 - 0.738 - ( 3.331 - max(0, 1.302 - 4.78+3.331))
=3.104

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

BCAL Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7.578/( ( (2.714 + max(1.356, 0)) + (2.393 + max(0.611, 0)) )/ 2 )
=-7.578/( ( 4.07 + 3.004 )/ 2 )
=-7.578/3.537
=-214.25 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.665) - (1.197 + 0 + 0.112)
=1.356

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.105 + 0 + 1.344) - (0.738 + 0 + 0.1)
=0.611

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BCAL Diagnostics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-7.034/29.972
=-23.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics EBIT Related Terms

BCAL Diagnostics EBIT Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics EBIT Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
EBIT
-4.10 -7.90 -6.36 -7.20

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.35 -4.01 -3.95 -3.25 -3.79

ASX:BDX vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, BCAL Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's EV-to-EBIT falls into.


BCAL Diagnostics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-7.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of A$-7.03 Mil mean?
BCAL Diagnostics (ASX:BDX) has a EBIT of A$-7.03 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BCAL Diagnostics.
Is BCAL Diagnostics' EBIT too high?
BCAL Diagnostics' current EBIT is A$-7.03 Mil.
How does BCAL Diagnostics' EBIT compare to TMO and DHR?
BCAL Diagnostics' EBIT of A$-7.03 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BCAL Diagnostics. BCAL Diagnostics's current EBIT is A$-7.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current EBIT of A$-7.03 Mil. The current EBIT is A$-7.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current EBIT is A$-7.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.